| SYNDAX PHARMACEU.DL-,0001 |
| USA |
| Gesundheit |
| US87164F1057 / A2AFL6 |
| 1T3 (Frankfurt) / SNDX (NASDAQ) |
| FRA:1T3, ETR:1T3, 1T3:GR, NASDAQ:SNDX |
| - |
| https://www.syndax.com/ |
|
Syndax Pharmaceuticals Inc. is a commercial stage oncology innovator focused on developing cancer therapies for areas of significant unmet medical need. The company's product portfolio includes Revuforj, a menin inhibitor approved for treating relaps..
>Volltext.. |
| 1478.48 Mio. EUR |
| 1472.69 Mio. EUR |
| 188.55 Mio. EUR |
| -193.84 Mio. EUR |
| -210.95 Mio. EUR |
| -2.42 EUR |
| 299.5 Mio. EUR |
| 113.51 Mio. EUR |
| -241.23 Mio. EUR |
| 4.09 |
| 365.64% |
| 31.23% |
| - |
| - |
| - |
| SYNDAX |
| 05.08.26 |
|
||||
|
||||
|
||||
|